Iovance Biotherapeutics, Inc. (IOVA): Price and Financial Metrics

Iovance Biotherapeutics, Inc. (IOVA): $14.03

0.12 (+0.86%)

POWR Rating

Component Grades

Momentum

C

Stability

F

Sentiment

Quality

D

Add IOVA to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#315 of 360

in industry

IOVA Price/Volume Stats

Current price $14.03 52-week high $18.33
Prev. close $13.91 52-week low $3.21
Day low $13.60 Volume 6,693,100
Day high $14.65 Avg. volume 10,486,419
50-day MA $11.38 Dividend yield N/A
200-day MA $7.52 Market Cap 3.92B

IOVA Stock Price Chart Interactive Chart >

IOVA POWR Grades

  • IOVA scores best on the Growth dimension, with a Growth rank ahead of 53.66% of US stocks.
  • IOVA's strongest trending metric is Quality; it's been moving down over the last 26 weeks.
  • IOVA ranks lowest in Stability; there it ranks in the 2nd percentile.

IOVA Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for IOVA is 0 -- better than just 8.17% of US stocks.
  • With a price/sales ratio of 2,859.63, IOVANCE BIOTHERAPEUTICS INC has a higher such ratio than 99.7% of stocks in our set.
  • Revenue growth over the past 12 months for IOVANCE BIOTHERAPEUTICS INC comes in at 197.06%, a number that bests 97.34% of the US stocks we're tracking.
  • If you're looking for stocks that are quantitatively similar to IOVANCE BIOTHERAPEUTICS INC, a group of peers worth examining would be ALLO, ALT, CLDX, ENTA, and ANAB.
  • IOVA's SEC filings can be seen here. And to visit IOVANCE BIOTHERAPEUTICS INC's official web site, go to www.iovance.com.

IOVA Valuation Summary

  • IOVA's price/sales ratio is 2942.9; this is 133668.18% higher than that of the median Healthcare stock.
  • IOVA's price/sales ratio has moved NA NA over the prior 161 months.

Below are key valuation metrics over time for IOVA.

Stock Date P/S P/B P/E EV/EBIT
IOVA 2023-12-29 2942.9 3.1 -4.8 -4.2
IOVA 2023-12-28 3105.8 3.3 -5.1 -4.5
IOVA 2023-12-27 2617.1 2.7 -4.3 -3.7
IOVA 2023-12-26 3218.0 3.4 -5.3 -4.6
IOVA 2023-12-22 3019.0 3.2 -4.9 -4.3
IOVA 2023-12-21 2856.0 3.0 -4.7 -4.1

IOVA Growth Metrics

    Its 4 year price growth rate is now at 444.33%.
  • Its 4 year net cashflow from operations growth rate is now at -315.8%.
  • Its 5 year net income to common stockholders growth rate is now at -98.2%.
Over the past 15 months, IOVA's revenue has gone down $0.

The table below shows IOVA's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 0 -268.935 -389.904
2022-06-30 0 -262.979 -376.408
2022-03-31 0 -239.352 -358.41
2021-12-31 0 -227.941 -342.252
2021-09-30 0 -236.784 -311.319
2021-06-30 0 -219.606 -283.768

IOVA's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • IOVA has a Quality Grade of D, ranking ahead of 7.09% of graded US stocks.
  • IOVA's asset turnover comes in at 0 -- ranking 441st of 682 Pharmaceutical Products stocks.
  • PPBT, TEVA, and PTE are the stocks whose asset turnover ratios are most correlated with IOVA.

The table below shows IOVA's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0 NA -0.418
2021-03-31 0 NA -0.414
2020-12-31 0 NA -0.482
2020-09-30 0 NA -0.580
2020-06-30 0 NA -0.686
2020-03-31 0 NA -0.793

IOVA Price Target

For more insight on analysts targets of IOVA, see our IOVA price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $40.31 Average Broker Recommendation 1.5 (Moderate Buy)

Iovance Biotherapeutics, Inc. (IOVA) Company Bio


Iovance Biotherapeutics, formerly known as Lion Biotechnologies, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company was founded in 2007 and is based in Woodland Hills, California.


IOVA Latest News Stream


Event/Time News Detail
Loading, please wait...

IOVA Latest Social Stream


Loading social stream, please wait...

View Full IOVA Social Stream

Latest IOVA News From Around the Web

Below are the latest news stories about IOVANCE BIOTHERAPEUTICS INC that investors may wish to consider to help them evaluate IOVA as an investment opportunity.

Why Iovance Biotherapeutics Stock Popped Today

Iovance rebounded nicely after yesterday's drop, which came after the FDA put a clinical hold on its cancer-therapy trial.

Yahoo | December 28, 2023

Iovance (IOVA) Falls After Clinical Update on Lung Cancer Drug

Iovance (IOVA) is likely to pause enrollment in the phase II IOV-LUN-202 study evaluating its tumor infiltrating lymphocyte therapy, LN-145, for treating non-small cell lung cancer. Stock declines.

Yahoo | December 28, 2023

3 Charts For Investors to Watch Thursday: GC Education, Iovance, Ethereum

These two stocks and one cryptocurrency are worth watching today. We discuss why and identify important chart levels to watch.

Yahoo | December 28, 2023

Gold nears $2100, biotech stocks on the move: Trending tickers

Gold (GC=F) prices are inching closer to $2,100 per ounce. It's an area that has been a bit of a resistance level for the precious metal. In the world of biotech, Cytokinetics (CYTK) shares soared more than 80% after a trial for its hear drug showed promising results. Meanwhile, Iovance Biotherapeutics (IOVA) shares fell 18% after the Food and Drug Administration paused clinical trials of a lung cancer treatment following the death of a patient. For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live.

Yahoo | December 27, 2023

FDA Slaps Clinical Hold On Iovance Biotherapeutics' Lung Cancer Study After Patient Death

Wednesday, Iovance Biotherapeutics Inc (NASDAQ: IOVA) announced a clinical program update for LN-145 TIL therapy in non-small lung cancer (NSCLC). The FDA placed a clinical hold on the IOV-LUN-202 trial on December 22, 2023, in response to a recently reported Grade 5 (fatal) serious adverse event potentially related to the non-myeloablative lymphodepletion pre-conditioning regimen. During the clinical hold, Iovance will pause enrollment and the LN-145 TIL treatment regimen for new patients in IO

Yahoo | December 27, 2023

Read More 'IOVA' Stories Here

IOVA Price Returns

1-mo 53.33%
3-mo 95.40%
6-mo 178.65%
1-year 121.64%
3-year -55.26%
5-year 36.08%
YTD 72.57%
2023 27.23%
2022 -66.53%
2021 -58.86%
2020 67.63%
2019 212.77%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!